Analyst Consensus ?
ConsensusBuy13 ratings
Bullish1184.6%
Neutral215.4%
Bearish00.0%
STERIS plc · STE · FY2025 Q3 · Calendar Q1 2025
STERIS: Recurring demand offsets equipment timing and legal risks
STERIS's recurring healthcare demand, services activity and bioprocessing strength support the operating outlook, but shipment timing, cost inflation, litigation and tariff exposure temper the case.
Reported Before market openNYSEHealthcare
$20.89B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $2.33
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $1.38B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+2.1%
Event window
SPY move
+0.3%
Same window
Abnormal move
+1.7%
Stock minus SPY
Volume
2.8×
Versus trailing sessions
Subsequent drift
+3.2%
Up to 20 sessions
STESPY benchmark
Ask FN2 about STE FY2025 Q3
Transcript, numbers and history already loaded
What drove STE's +2.1% move after FY2025 Q3 earnings?What changed in STE's guidance and outlook in FY2025 Q3?Give me the bull and bear case for STE after FY2025 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The latest analysis shows continued recurring-demand strength and improved healthcare margins, alongside delayed capital-equipment shipments, higher litigation expense, and narrower FY2025 organic-growth and adjusted-EPS guidance.
Guidance delta
Guidance was narrowed from the prior quarter: organic growth is about 6% and adjusted EPS is $9.05-$9.15; the $700 million free-cash-flow target remains unchanged.
Key takeaways
- Healthcare consumables and services supported growth and margin expansion.
- AST services benefited from stronger bioprocessing demand and grew organically.
- Capital-equipment shipments lagged because of timing, while litigation and tariff exposure remain risks.
Management priorities
- Maintain the FY2025 free-cash-flow target and planned capital spending.
- Invest in endoscopy reprocessing and sterile-processing equipment research and development.
- Pursue bioprocessing consumables and services growth while managing compliance and supply-chain risks.
Follow STE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$219.68Current
$245Low
$264.75Average
$275High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 12, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Aug 7, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 7, 2026 |
| Keybanc | Overweight | Overweight | Maintain | May 13, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 8, 2025 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | May 16, 2025 |
| Stephens & Co. | Overweight | Overweight | Maintain | May 15, 2025 |
| Needham | Hold | Hold | Maintain | Apr 7, 2025 |
| Baird | Outperform | Outperform | Maintain | Aug 11, 2021 |
| Sidoti & Co. | Buy | Buy | Maintain | Nov 25, 2020 |
| Raymond James | Outperform | Strong Buy | Downgrade | Nov 25, 2020 |
| Griffin Securities | Hold | Buy | Downgrade | Nov 25, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 25, 2020 |
| B of A Securities | Buy | Buy | Maintain | Mar 15, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $219.68. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Patrick Wood | $275 | $218.4 | +25.2% | Jul 28, 2026 |
| Piper Sandler | Jason Bednar | $270 | $216.18 | +22.9% | May 21, 2026 |
| KeyBanc | Brett Fishbin | $269 | $210.85 | +22.5% | May 13, 2026 |
| Piper Sandler | Jason Bednar | $260 | $221.15 | +18.4% | Oct 24, 2024 |
| KeyBanc | Brett Fishbin | $265 | $241.1 | +20.6% | Sep 3, 2024 |
| Piper Sandler | Jason Bednar | $225 | $225.94 | +2.4% | May 10, 2024 |
| Wolfe Research | Mike Polark | $245 | $216.65 | +11.5% | Apr 4, 2024 |
Track every rating change on STE the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationSTERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
Historical context
All STE earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
Get the STE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-24T15:56:47.382393+00:00
- Polygon adjusted daily market bars · 2026-10-12T13:30:43.458028+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-12T13:30:43.454742+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-12. For educational purposes only; not investment advice.